QurAlis to Present Data on Two Precision Medicine Programs (Kv7 and TBK1) at MNDA 31st International Symposium on ALS/MND – Press Release

CAMBRIDGE, Mass.–(Business Wire)–QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced that the company will present two posters featuring data from two of the company’s preclinical precision medicine ALS programs at the Motor Neuron Disease Association (MNDA) 31st International Symposium on ALS/MND, being held virtually on December 9-11, 2020.

QurAlis co-founders and Harvard professors Kevin Eggan, Ph.D. and Clifford Woolf, M.D., Ph.D., members of the QurAlis Scientific and Clinical Advisory Boards, Brian Wainger, M.D., Ph.D. (Massachusetts General Hospital) and Merit Cudkowicz, M.D., M.Sc. (Massachusetts General Hospital), and other authors recently published in JAMA Neurology the results of a clinical study investigating the therapeutic potential of Kv7 agonism in ALS. The clinical data support QurAlis’ belief that a safe Kv7 opener could be an effective disease-modifying therapy for ALS patients with motor system hyperexcitability, an approach that QurAlis is pursing with its preclinical program investigating the regulation of the Kv7.2/7.3 ion channel.

The poster presentations will share, for the first time publicly, results from preclinical studies of QurAlis’ program investigating a novel Kv7.2/7.3 ion channel agonist as a potential treatment for motor neuron hyperexcitability and excitotoxicity, as well as its program targeting the TBK1 autophagy pathway.

“While KV7 agonists have shown great potential as a treatment for the 20-50% of ALS patients who present with hyperexcitability in their motor system, they can often cause undesired side effects such as dizziness and fatigue,” said Daniel Elbaum, Ph.D., Chief Scientific Officer of QurAlis. “The preclinical data we will be presenting show that the improved channel specificity of our novel Kv7.2/7.3 agonist could translate into an improved clinical safety profile with significant reduction in off-target adverse events. We look forward to sharing the full results of this preclinical study as well as discussing our autophagy program at the MNDA 31st International Symposium on ALS/MND.”

Details of the presentations are as follows:

Title: TBK1 Autophagy Pathway Disease Mechanisms in ALS

Authors: Erika Norabuena; Clinton Bourbonais; Kasper Roet, Ph.D.; Kevin Eggan, Ph.D.; Daniel Elbaum, Ph.D.; Sandy Hinckley, Ph.D.

Presenting Author: Erika Norabuena

Date/Time: December 9, 2020, 12:10pm-12:50pm ET

Poster/Abstract Number: TST-07

Link to abstract

Title: QRA-244 a Potent, Selective KCNQ2/3 Opener and a Potential Therapy for Motor System Hyperexcitability induced Disease Progression in ALS patients

Authors: Daniel Elbaum, Ph.D.; Sandy Hinckley, Ph.D.; Kasper Roet, Ph.D.

Presenting Author: Daniel Elbaum, Ph.D.

Date/Time: December 11, 2020, 7:05am-7:50am ET

Poster/Abstract Number: TST-20

Link to abstract

About ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease impacting nerve cells in the brain and spinal cord. ALS breaks down nerve cells, reducing muscle function and causing loss of muscle control. ALS can be traced to mutations in over 25 different genes and is often caused by a combination of multiple sub-forms of the condition. Its average life expectancy is three years, and there is currently no cure for the disease.

About QurAlis Corporation

QurAlis is bringing hope to the

Read More

Sidra’s Precision Medicine symposium ready for launch

Sidra Medicine has announced that it is all set to host the fifth edition of its flagship ‘Precision Medicine and Functional Genomics 2020’ (PMFG 2020). The symposium will be held online from December 5-7, providing resourceful ‘remote learning’ opportunities on account of the current pandemic restrictions, according to a press statement.
Attendees to PMFG 2020 will receive 14.25 hours credits for learning as approved by the Qatar Council of Healthcare Practitioners. The conference is being billed as one of the major scientific symposiums from the Middle East, dedicated to covering topics relevant to the current pandemic as well as the importance of precision medicine, the statement notes.
Registered attendees will be able to access various sessions – from live and on-demand programming – and hear from notable local and international speakers. PMFG 2020 will dedicate a special session on Covid-19, which sheds light on the testing and treatment strategies that are now in place, including examples of recent methods developed and enhanced in Qatar.
“Precision Medicine is a key focus area for our conference programme and indeed, for Qatar. Sidra Medicine has been working closely with our local partners to build capacity in this area in recent years, and considering growing global interest in making precision medicine a reality for patients, we are excited to share early success stories. PMFG 2020 will provide an engaging platform for speakers to present best practices, discuss case studies and explore future opportunities. It will also be a forum to present innovations using precision technologies, in tackling a variety of ongoing health challenges such as diabetes, cancer and Covid-19,” said Dr Khalid Fakhro, chief research officer, Sidra Medicine.
PMFG 2020 will feature global and local thought leaders, including Prof Sir Mark Caulfield – chief scientist, Genomics England, UK, who will talk about the ‘100,000 Genomes Project’ and health transformation. Other notable speakers include Prof Adolfo Garcia-Sastre, professor of Medicine and Microbiology, The Icahn School of Medicine, US, discussing the development of Covid-19 vaccines; Dr Stephen Hunger, chief, Division of Paediatric Oncology, and director, Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, US, discussing implementing new precision medicine and immunotherapy strategies in paediatric acute lymphoblastic leukaemia.
In addition, Dr Alan Shuldiner, vice-president, Regeneron Pharmaceuticals, Inc, New York, US, will discuss ‘The Regeneron Genetics Center at 1 million exomes: What have we learned’; in addition to Dr Virginia Pascual, Ronay Menschel Professor of Paediatrics, director, Drukier Institute for Children’s Health, Weill Cornell Medicine – New York, US, talking about ‘A Personalised Approach to Understand Systemic Lupus Erythematosus Heterogeneity’.
To register, preview the full agenda and see the speakers’ list, one has to visit

Read More

Ra Medical Systems to Feature the Pharos Optimized Excimer Laser at the Virtual New Frontiers in Cosmetic Medicine & Medical Dermatology Symposium

CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces it will feature the Pharos excimer laser at the New Frontiers in Cosmetic Medicine & Medical Dermatology Symposium 2020 Virtual Meeting being held November 21, 2020.

“We are delighted to showcase our Pharos excimer laser at this conference,” said Will McGuire, Ra Medical Systems CEO. “Pharos provides topical treatment of common skin disorders including psoriasis, vitiligo, atopic dermatitis and leukoderma and is a lower cost and safe alternative to immunosuppressive agents. During the pandemic, Pharos may play a particularly valuable role for patients who may be otherwise immunocompromised.”

About the New Frontiers in Cosmetic Medicine & Medical Dermatology Conference

New Frontiers in Cosmetic Medicine Symposium will deal with the latest developments in cosmetic dermatology, cosmetic medicine, and anti-aging medicine. It is designed for an audience of physicians, physician assistants, nurses and nurse practitioners who work under the direct supervision of dermatologists, facial plastic surgeons, oculoplastic surgeons, and plastic surgeons, and commonly assist with cosmetic surgery and medicine. More information is available at

About Ra Medical Systems

Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases. In May 2017 the DABRA excimer laser system received FDA 510(k) clearance in the U.S. for crossing chronic total occlusions, or CTOs, in patients with symptomatic infrainguinal lower extremity vascular disease with an intended use for ablating a channel in occlusive peripheral vascular disease. The Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. DABRA and Pharos are both based on Ra Medical’s core excimer laser technology platform and deploy similar mechanisms of action. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in controlled environments.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Ra Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern Ra Medical’s future expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding the timing and potential outcome of the DABRA atherectomy clinical study. Ra Medical’s expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied by such forward-looking statements. The potential risks and

Read More

Qatar- Registration open for Sidra Medicine’s precision medicine symposium

(MENAFN – The Peninsula) Doha: Sidra Medicine is pleased to announce that registrations to its virtual Precision Medicine and Functional Genomics Symposium (PMFG 2020) are now open. The symposium will be hosted online from December 5 to 7.

PMFG 2020 Organizing Co-Chair, Dr. Bernice Lo, Investigator at Sidra Medicine said: ‘We have finalised some very topical discussions this year, including precision medicine solutions for managing COVID-19. We are also going to cover the large-scale discoveries that drive precision medicine as well as lessons from industry and biotechnology sectors.

Attendees to PMFG 2020 will receive 14.25 hours learning credits as approved by the Qatar Council of Healthcare Practitioners. Speakers to PMFG 2020 include Sir Mark Caulfield from Genomics England; Dr. Adolfo Garcia-Sastre from the Icahn School of Medicine at Mount Sinai; Dr. Ingrid Scheffer from the University of Melbourne; Dr. Paul Thompson from the University of Southern California and Dr. Virginia Pascual from Cornell University.


Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Source Article

Read More

National Academy of Medicine president to give keynote address at 2020 CVBE Symposium – School of Engineering

The 2020 Progenitor Cell Translation Consortium (PCTC) Cardiovascular Bioengineering (CVBE) Symposium co-hosted by the UAB Department of Biomedical Engineering, will feature a keynote address by Victor Dzau, M.D., president of the National Academy of Medicine. Dzau, a professor of Medicine at Duke University will speak on “The Future of Heart Failure Therapy/Paracrine Mechanism of Stem Cell Therapy,” on December 5, 2020 at 9:10 a.m.

dzauSource: medicine.duke.eduDue to the worldwide outbreak of coronavirus (COVID-19), the symposium will be held in a virtual format via Zoom for the first time. The event was originally scheduled for the spring in Göttingen, Germany, and was anticipated to draw speakers and guests from around the globe. This collaborative conference, focusing on cardiac gene and cell therapy topics, is co-hosted and co-organized by UAB BME Chair Jay Zhang, M.D., Ph.D., and Wolfram Zimmerman, Ph.D., of the University Medical Center Göttingen. Topics addressed will include areas of gene editing, induced pluripotent stem cells, cardiac stem cells in the context of heart failure, cardiovascular bioengineering, vascular tissue engineering, cardiac development, exosomes, microRNAs, and mitochondria.

In addition to his role of president of the National Academy of Medicine (NAM) (formerly the Institute of Medicine), Dzau also serves as the vice chair of the National Research Council and is chancellor emeritus and James B. Duke Professor of Medicine at Duke University Health System. Prior to these roles, he was the Hersey Professor of Theory and Practice of Medicine and Chairman of Medicine at Harvard Medical School’s Brigham and Women’s Hospital, and Chairman of the Department of Medicine and Director of the Falk Cardiovascular Research Center at Stanford University. Dzau is a prominent world health leader and advises governments, corporations, and universities worldwide. He has also made a major impact on health and medicine through his seminal research in cardiovascular medicine and genetics and his leadership in health innovation.

Registration is free, but will be required for access to the symposium. Register online at:

Source Article

Read More

Registrations open for Sidra Medicine’s precision medicine symposium

Sidra Medicine has opened registrations for its virtual Precision Medicine and Functional Genomics Symposium (PMFG), to be held online from December 5 to 7.

PMFG 2020 Organising co-chair, Dr Bernice Lo, investigator at Sidra Medicine said, “We have finalised some very topical discussions this year including precision medicine solutions for managing Covid-19. We are also going to cover the large-scale discoveries that drive precision medicine as well as lessons from industry and biotechnology sectors.”

International speakers to PMFG 2020 include Mark Caulfield from Genomics England; Dr Adolfo Garcia-Sastre from the Icahn School of Medicine at Mount Sinai; Dr Ingrid Scheffer from the University of Melbourne; Dr Paul Thompson from the University of Southern California and Dr Virginia Pascual from Cornell University.

In addition, attendees will also have access to presentations from Dr Alan Shuldiner from Regeneron Genetics Centre; Dr Stuart Tangye from the Garvan Institute and Dr Lara Mangravite from Sage Bionetworks.

Dr Damien Chaussabel, organising co-chair of PMFG 2020 and director of Sidra Medicine’s Immunology Programme said, “Our cohort of renowned speakers will share their insights about the advancements in precision medicine through data-driven science and research. We are excited that Sidra Medicine is in a very unique position to highlight its own precision medicine journey so far. We look forward to welcoming delegates online from all over the world for this year’s symposium.”

PMFG 2020 will feature live and on-demand programming from invited speakers, as well as provide opportunities for talks from competitive abstract submissions. It will bring together researchers, academics, healthcare professionals, policy makers, partners and the community, to explore the latest developments and innovations in genomics research and how they translate into precision medicine solutions.

Source Article

Read More

Phosplatin Therapeutics Announces Presentation of Research into PT-112 Mechanism of Action at the 32nd EORTC-NCI-AACR Virtual Symposium

NEW YORK, Oct. 20, 2020 /PRNewswire/ — Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that data revealing novel mechanistic attributes of its lead candidate PT-112, an immunogenic cell death (ICD) inducer under Phase 2 development, will be presented at the 32nd Symposium of the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) taking place virtually from October 24-25.

(PRNewsfoto/Phosplatin Therapeutics LLC)
(PRNewsfoto/Phosplatin Therapeutics LLC)


PT-112, A First-In-Class Pyrophosphate-Platinum Conjugate, Selectively Targets Highly Glycolytic Tumor Cells (catalog number 188)

Abstract availability: 

Saturday, October 24, 2020 on EORTC-NCI-AACR symposium site and on the Phosplatin Therapeutics web site


New Drugs Poster Session (code 380)

Lead Author: 

A. Anel, University of Zaragoza /Aragón Health Research Institute, Biochemistry and Molecular and Cell Biology, Zaragoza, Spain

Building upon prior publication of the ICD effects of PT-112, the body of work to be presented is part of an effort to understand the metabolic pathways and cellular targets affected by PT-112 upstream of ICD initiation. “The data to be reported at the 32nd EORTC-NCI-AACR Virtual Symposium advance the body of knowledge around PT-112’s pleiotropic mechanism of action and provide valuable information on further potential clinical applications of PT-112. As we continue our clinical study of this unique compound in patients with challenging cancers, such insights are important,” said Robert Fallon, co-founder and chief executive officer, Phosplatin Therapeutics. “We are pleased to co-present this body of work under our fruitful collaboration with the Anel lab at the University of Zaragoza, Spain.”

About PT-112

PT-112 is a novel small molecule conjugate of pyrophosphate that possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 represents the best-in-class small molecule inducer of this immunological form of cancer cell death and is currently under Phase II development. The first in-human study of PT-112 demonstrated an attractive safety profile and evidence of long-lasting responses among heavily pre-treated patients and won “Best Poster” within the Developmental Therapeutics category at the ESMO 2018 Annual Congress. The novelty of PT-112’s pyrophosphate moiety also results in osteotropism, or the propensity of the drug to reach the mineralized bone. This property is of interest in cancer types that originate in or metastasize to the bone. The combination Phase Ib study of PT-112 with PD-L1 checkpoint inhibitor avelumab in solid tumors was reported in an oral presentation at the ESMO 2020 Virtual Congress.

About Phosplatin Therapeutics

Phosplatin Therapeutics is a privately held, clinical stage pharmaceutical company that holds exclusive global license to phosphaplatins, a family of small molecules rationally designed to circumvent the mechanisms of drug resistance and toxicity commonly associated with chemotherapeutic regimens. The company’s lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique

Read More